CreatorsPublishersAdvertisers
View more in
Health

Melflufen/Dexamethasone Improves PFS in Transplant-Naïve Relapsed/Refractory Multiple Myeloma

onclive.com
 2021-09-12

Melphalan flufenamide (melflufen) plus dexamethasone demonstrated an improvement in progression-free survival vs pomalidomide/dexamethasone in patients with transplant-naïve relapsed/refractory multiple myeloma. Melphalan flufenamide (melflufen) plus dexamethasone demonstrated an improvement in progression-free survival vs pomalidomide/dexamethasone in patients with transplant-naïve relapsed/refractory multiple myeloma, according to phase 3 data of the OCEAN (OP-103) study...

www.onclive.com

Comments / 0

Comments / 0